TELA vs. CVRX, ZIMV, SMTI, DRTS, ELMD, INGN, NYXH, ZYXI, CATX, and LUNG
Should you be buying TELA Bio stock or one of its competitors? The main competitors of TELA Bio include CVRx (CVRX), ZimVie (ZIMV), Sanara MedTech (SMTI), Alpha Tau Medical (DRTS), Electromed (ELMD), Inogen (INGN), Nyxoah (NYXH), Zynex (ZYXI), Perspective Therapeutics (CATX), and Pulmonx (LUNG). These companies are all part of the "medical equipment" industry.
TELA Bio vs.
CVRx (NASDAQ:CVRX) and TELA Bio (NASDAQ:TELA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
In the previous week, CVRx and CVRx both had 2 articles in the media. CVRx's average media sentiment score of 1.34 beat TELA Bio's score of 0.78 indicating that CVRx is being referred to more favorably in the media.
TELA Bio received 28 more outperform votes than CVRx when rated by MarketBeat users. Likewise, 74.68% of users gave TELA Bio an outperform vote while only 72.09% of users gave CVRx an outperform vote.
75.3% of CVRx shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 18.9% of CVRx shares are owned by company insiders. Comparatively, 6.0% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
CVRx has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
CVRx has higher earnings, but lower revenue than TELA Bio. CVRx is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.
TELA Bio has a net margin of -60.49% compared to CVRx's net margin of -123.75%. CVRx's return on equity of -89.06% beat TELA Bio's return on equity.
CVRx currently has a consensus price target of $17.00, suggesting a potential upside of 6.38%. TELA Bio has a consensus price target of $9.25, suggesting a potential upside of 250.38%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than CVRx.
Summary
TELA Bio beats CVRx on 9 of the 17 factors compared between the two stocks.
Get TELA Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TELA Bio Competitors List
Related Companies and Tools
This page (NASDAQ:TELA) was last updated on 2/1/2025 by MarketBeat.com Staff
